188 related articles for article (PubMed ID: 25884855)
1. The differential anti-tumour effects of zoledronic acid in breast cancer - evidence for a role of the activin signaling pathway.
Wilson C; Ottewell P; Coleman RE; Holen I
BMC Cancer; 2015 Feb; 15():55. PubMed ID: 25884855
[TBL] [Abstract][Full Text] [Related]
2. Oestrogen receptor positive breast cancer metastasis to bone: inhibition by targeting the bone microenvironment in vivo.
Holen I; Walker M; Nutter F; Fowles A; Evans CA; Eaton CL; Ottewell PD
Clin Exp Metastasis; 2016 Mar; 33(3):211-24. PubMed ID: 26585891
[TBL] [Abstract][Full Text] [Related]
3. Zoledronic acid sensitizes breast cancer cells to fulvestrant via ERK/HIF-1 pathway inhibition in vivo.
Jia X; Cheng J; Shen Z; Shao Z; Liu G
Mol Med Rep; 2018 Apr; 17(4):5470-5476. PubMed ID: 29393454
[TBL] [Abstract][Full Text] [Related]
4. Novel retinoic acid metabolism blocking agents have potent inhibitory activities on human breast cancer cells and tumour growth.
Patel JB; Mehta J; Belosay A; Sabnis G; Khandelwal A; Brodie AM; Soprano DR; Njar VC
Br J Cancer; 2007 Apr; 96(8):1204-15. PubMed ID: 17387344
[TBL] [Abstract][Full Text] [Related]
5. Zoledronic acid-induced cytotoxicity through endoplasmic reticulum stress triggered REDD1-mTOR pathway in breast cancer cells.
Lan YC; Chang CL; Sung MT; Yin PH; Hsu CC; Wang KC; Lee HC; Tseng LM; Chi CW
Anticancer Res; 2013 Sep; 33(9):3807-14. PubMed ID: 24023313
[TBL] [Abstract][Full Text] [Related]
6. Macrophages as potential targets for zoledronic acid outside the skeleton-evidence from in vitro and in vivo models.
Rogers TL; Wind N; Hughes R; Nutter F; Brown HK; Vasiliadou I; Ottewell PD; Holen I
Cell Oncol (Dordr); 2013 Dec; 36(6):505-14. PubMed ID: 24177992
[TBL] [Abstract][Full Text] [Related]
7. New self-assembly nanoparticles and stealth liposomes for the delivery of zoledronic acid: a comparative study.
Marra M; Salzano G; Leonetti C; Porru M; Franco R; Zappavigna S; Liguori G; Botti G; Chieffi P; Lamberti M; Vitale G; Abbruzzese A; La Rotonda MI; De Rosa G; Caraglia M
Biotechnol Adv; 2012; 30(1):302-9. PubMed ID: 21741464
[TBL] [Abstract][Full Text] [Related]
8. Calycosin inhibits the in vitro and in vivo growth of breast cancer cells through WDR7-7-GPR30 Signaling.
Tian J; Wang Y; Zhang X; Ren Q; Li R; Huang Y; Lu H; Chen J
J Exp Clin Cancer Res; 2017 Nov; 36(1):153. PubMed ID: 29096683
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant chemotherapy with or without zoledronic acid in early breast cancer--a randomized biomarker pilot study.
Winter MC; Wilson C; Syddall SP; Cross SS; Evans A; Ingram CE; Jolley IJ; Hatton MQ; Freeman JV; Mori S; Holen I; Coleman RE
Clin Cancer Res; 2013 May; 19(10):2755-65. PubMed ID: 23515409
[TBL] [Abstract][Full Text] [Related]
10. The combined use of Camellia sinensis and metronomic zoledronic acid in a breast cancer-induced osteolysis mouse model.
Luo KW; Ko CH; Yue GG; Gao S; Lee JK; Li G; Fung KP; Leung PC; Evdokiou A; Lau CB
J Cancer Res Clin Oncol; 2015 Jun; 141(6):1025-36. PubMed ID: 25431338
[TBL] [Abstract][Full Text] [Related]
11. Combination therapy with zoledronic acid and cetuximab effectively suppresses growth of colorectal cancer cells regardless of KRAS status.
Kato J; Futamura M; Kanematsu M; Gaowa S; Mori R; Tanahashi T; Matsuhashi N; Yoshida K
Int J Cancer; 2016 Mar; 138(6):1516-27. PubMed ID: 26437179
[TBL] [Abstract][Full Text] [Related]
12. Estradiol impairs the antiproliferative and proapoptotic effect of Zoledronic acid in hormone sensitive breast cancer cells in vitro.
Gschwantler-Kaulich D; Weingartshofer S; Grunt TW; Mairhofer M; Tan Y; Gamper J; Singer CF
PLoS One; 2017; 12(9):e0185566. PubMed ID: 28945801
[TBL] [Abstract][Full Text] [Related]
13. Hydrogen sulfide-releasing aspirin suppresses NF-κB signaling in estrogen receptor negative breast cancer cells in vitro and in vivo.
Chattopadhyay M; Kodela R; Nath N; Barsegian A; Boring D; Kashfi K
Biochem Pharmacol; 2012 Mar; 83(6):723-32. PubMed ID: 22209867
[TBL] [Abstract][Full Text] [Related]
14. Benzopyran derivative CDRI-85/287 induces G2-M arrest in estrogen receptor-positive breast cancer cells via modulation of estrogen receptors α- and β-mediated signaling, in parallel to EGFR signaling and suppresses the growth of tumor xenograft.
Saxena R; Fatima I; Chandra V; Blesson CS; Kharkwal G; Hussain MK; Hajela K; Roy BG; Dwivedi A
Steroids; 2013 Nov; 78(11):1071-86. PubMed ID: 23891847
[TBL] [Abstract][Full Text] [Related]
15. R115777 (Zarnestra)/Zoledronic acid (Zometa) cooperation on inhibition of prostate cancer proliferation is paralleled by Erk/Akt inactivation and reduced Bcl-2 and bad phosphorylation.
Caraglia M; Marra M; Leonetti C; Meo G; D'Alessandro AM; Baldi A; Santini D; Tonini G; Bertieri R; Zupi G; Budillon A; Abbruzzese A
J Cell Physiol; 2007 May; 211(2):533-43. PubMed ID: 17192846
[TBL] [Abstract][Full Text] [Related]
16. Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer.
Ottewell PD; Mönkkönen H; Jones M; Lefley DV; Coleman RE; Holen I
J Natl Cancer Inst; 2008 Aug; 100(16):1167-78. PubMed ID: 18695136
[TBL] [Abstract][Full Text] [Related]
17. The PI3K/mTOR dual inhibitor P7170 demonstrates potent activity against endocrine-sensitive and endocrine-resistant ER+ breast cancer.
Bean JR; Hosford SR; Symonds LK; Owens P; Dillon LM; Yang W; Shee K; Schwartz GN; Marotti JD; Muller KE; Rosenkranz KM; Barth RJ; Chen VS; Agarwal VR; Miller TW
Breast Cancer Res Treat; 2015 Jan; 149(1):69-79. PubMed ID: 25491778
[TBL] [Abstract][Full Text] [Related]
18. Zoledronic acid inhibits proliferation of human fibrosarcoma cells with induction of apoptosis, and shows combined effects with other anticancer agents.
Koto K; Murata H; Kimura S; Horie N; Matsui T; Nishigaki Y; Ryu K; Sakabe T; Itoi M; Ashihara E; Maekawa T; Fushiki S; Kubo T
Oncol Rep; 2010 Jul; 24(1):233-9. PubMed ID: 20514467
[TBL] [Abstract][Full Text] [Related]
19. In vitro and in vivo effects of photodynamic therapy on metastatic breast cancer cells pre-treated with zoledronic acid.
Akens MK; Wise-Milestone L; Won E; Schwock J; Yee AJ; Wilson BC; Whyne CM
Photodiagnosis Photodyn Ther; 2014 Sep; 11(3):426-33. PubMed ID: 25176573
[TBL] [Abstract][Full Text] [Related]
20. Involvement of the mevalonate pathway in the antiproliferative effect of zoledronate on ACHN renal cell carcinoma cells.
Fujita M; Tohi M; Sawada K; Yamamoto Y; Nakamura T; Yagami T; Yamamori M; Okamura N
Oncol Rep; 2012 May; 27(5):1371-6. PubMed ID: 22322451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
